Abstract: A series of piperazin-1-yl substituted unfused heterobiaryls was synthesized as ligands of the 5-HT 7 receptors. The goal of this project was to elucidate the structural features that affect the 5-HT 7 binding affinity of this class of compounds represented by the model ligand 4-(3-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (2). The SAR studies included systematical structural changes of the pyrimidine core moiety in 2 to quinazoline, pyridine and benzene, changes of the 3-furyl group to other heteroaryl substituents, the presence of various analogs of the 4-methylpiperazin-1-yl group, as well as additional substitutions at positions 5 and 6 of the pyrimidine. Substitution of position 6 of the pyrimidine in the model ligand with an alkyl group results in a substantial increase of the binding affinity (note a change in position numbers due to the nomenclature rules). It was also demonstrated that 4-(3-furyl) moiety is crucial for the 5-HT 7 binding affinity of the substituted pyrimidines, although, the pyrimidine core can be replaced with a pyridine ring without a dramatic loss of the binding affinity. The selected ethylpyrimidine (12) and butylpyrimidine (13) analogs of high 5-HT 7 binding affinity showed antagonistic properties in cAMP functional test and varied selectivity profile-compound 12 can be regarded as a dual 5-HT 7 /5-HT 2A R ligand, and 13 as a multi-receptor (5-HT 7 , 5-HT 2A , 5-HT 6 and D 2 ) agent.
Introduction
For more than 60 years, the studies on the role of serotonin (5-HT) within the central nervous system (CNS) have constantly provided evidence of the involvement of 5-HT receptors in the action of various psychiatric drugs. It is now evident that deregulation of serotonergic signaling is associated with pathogenesis of severe neuropsychological disorders like depression [1, 2] Alzheimer's
The classical alkylation and acylation reactions of 1 provided facile entry to compounds 3-10 (Scheme 2). A similar strategy afforded a piperazinium derivative 47 (see Experimental). It was also found that the conjugate addition reaction of dimethylamine with 2-chloro-4-vinylquinazoline [27, 28] proceeds cleanly to furnish 2-chloro-4-(2-dimethylamino)ethyl substituted quinazoline, the subsequent treatment of which with N-methylpiperazine yielded the desired product 50 (Scheme 5).
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Pharmacology
Novel scaffold endowed with 5-HT 7 R activity was identified by screening of the in-house compound library in a single compound concentration of 1 µM in a competition radioligand binding assay using [ 3 H]5-CT and HEK293 cells overexpressing the human 5-HT 7b receptors. Compounds showing >60% of inhibition, namely (4-(3-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (2) and its two derivatives 11 and 18 were further tested in full binding experiments, and, as for all the newly synthesized compounds (1, 3-10, 12-17 and 19-71), 5-HT 7 R affinity (K i values˘SD) was determined in at least two independent experiments run in triplicate [31] . The functional properties of two selected compounds 12 and 13 active on 5-HT 7 R were further evaluated using their ability to inhibit cAMP production induced by 5-CT (10 nM) in the same cellular system [32, 33] . In addition, compounds 12 and 13 were evaluated for their affinity at three other serotonergic receptors: 5-HT 1A , 5-HT 2A , 5-HT 6 and dopaminergic D 2 in standard competition binding assays by use of the appropriate radioligand: 
Discussion
The objective of this study was to determine which combinations of structural features affect the 5-HT 7 binding affinity of unfused heterobiaryls. The intended SAR studies included synthesis of new analogs of the model compound 2 and encompassed the following points: (1) substitution of the amino group within the piperazine ring; (2) introduction of alkyl, amino and bulky substituents into positions 4/6 and/or 5 of the pyrimidine ring; (3) modifications of the heteroaryl group in position 4/6 of the pyrimidine; (4) replacement of the piperazinyl group by other amino substituents; and (5) synthesis of a series of pyridines and benzenes allowing comparison of the influence of the central ring nitrogen atom(s) on the ligand affinity.
First, investigating the influence of substituents at the basic piperazine atom, it was found that unsubstituted (1), simple alkyls (3 and 4), arylalkyl (7), hydroxyalkyl (8) or even esters (9 and 10) provide a similar level of 5-HT 7 R affinity (K i = 1.4-10 nM) as methylated hit compound 2 (K i = 7.2 nM). Slight decrease in 5-HT 7 R affinity is observed for benzyl derivative 5 (K i = 25 nM) which is probably caused by a negative steric influence of the phenyl group on the key interaction between a protonated nitrogen and aspartic acid (D3.32) residue in the receptor [35] . Moreover, with the benzoyl group (6), there is an obvious negative effect on the affinity (K i = 1405 nM) that arises from diminished basicity of the piperazine nitrogen atom (Table 1) .
In the literature, piperazine has been often a key element of 5-HT 7 R ligands [22] , and it is also optimal for heterobiaryl compounds, as its replacement results in decreased affinity (Table 2) . Indeed, introduction of homopiperazine leads to ligand with a moderate affinity for 5-HT 7 R (42, K i = 148 nM), whereas no affinity is observed for piperidine (43) and morpholine (44) derivatives that lack a basic nitrogen atom. In the group of compounds incorporating sterically hindered amines (45-47), only the ligand with positively charged quaternary nitrogen atom displayed moderate 5-HT 7 R affinity (47, K i = 299 nM). than their 2-furyl (26, 29) and 2-thienyl (32) counterparts. Replacement of the 3-furyl group for o-, m-, p-hydroxyphenyl (33) (34) (35) , pyridin-3-yl (39), thiazol-2-yl (40) or imidazol-1-yl (41) group as well as benzo-fused heterocyclic (36-38) moieties does not furnish ligands with noteworthy affinity for 5-HT7R (Ki > 1000 nM). Thus, it appears that the 3-furyl group is necessary for a high affinity of 5-HT7R ligands or, alternatively, a 3-thienyl moiety but with an appropriate enhancing substitutent at position 6 of the pyrimidine ring (Table 1) . 
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Next it was found that quinazoline derivatives (48-50), which can be treated as 5,6-disubstituted pyrimidine analogs, were inactive (Ki > 1910 nM). This result is fully consistent with our finding that substitution at position 5 is highly detrimental for 5-HT7R affinity (Table 3) . Having established reasonable SAR around pyrimidine central ring, we focused our attention on the role of the pyrimidine core itself, analyzing a series of substituted pyridine-and phenyl-piperazine analogs. The pyridine derivatives (51-59) were then synthesized to determine whether both nitrogen atoms within the central heterocycle are needed for the ligand to retain affinity for the binding pocket of the receptor (Table 4 ). The biological data show that both isomeric 4-(3-furyl) (51) and 6-(3-furyl) (57) pyridine ligands still demonstrate high affinities for the 5-HT7R (Ki = 17 nM and 8 nM, respectively). However, for the 2-furyl derivatives, position 4 (52 Ki = 307 nM) is preferred over
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Having established reasonable SAR around pyrimidine central ring, we focused our attention on the role of the pyrimidine core itself, analyzing a series of substituted pyridine-and phenyl-piperazine analogs. The pyridine derivatives (51-59) were then synthesized to determine whether both nitrogen atoms within the central heterocycle are needed for the ligand to retain affinity for the binding pocket of the receptor (Table 4 ). The biological data show that both isomeric 4-(3-furyl) (51) and 6-(3-furyl) (57) After finding that the pyrimidine core can be safely replaced with a pyridine ring, our attention was turned to compounds devoid of any nitrogen atoms within the central moiety of a ligand (Table 5) . 3-Furyl (60, Ki = 31 nM) and 3-thienyl (66, Ki = 342 nM) benzene analogs show significant 5-HT7R affinities, although they are 2-and 4-fold less active than their pyrimidine and pyridine equivalents. 5-HT7R affinities of 2-furyl (63, Ki = 914 nM) and 2-thienyl (69, Ki = 542 nM) derivatives remain at moderate levels. Consequently, introduction of methyl groups into position 5 of 1,3-disubstituted benzene analogs results in 2-to 7-fold increases of the binding properties (64, Ki = 312 nM; 67, Ki = 47 nM and 70, Ki = 297 nM), except for the 3-furyl ligand (61, Ki = 37 nM) which stays equipotent to its unsubstituted counterpart. Surprisingly, the n-butyl substituted benzene derivatives are lower in 5-HT7R affinity (62, Ki = 106 nM; 65, Ki = 743 nM; 68, Ki = 263 nM and 71, Ki = 734 nM). The observed phenomenon may arise from higher lipophilicity of the ligands, which increases non-specific interactions with the tested 5-HT7 receptor. After finding that the pyrimidine core can be safely replaced with a pyridine ring, our attention was turned to compounds devoid of any nitrogen atoms within the central moiety of a ligand (Table 5) . 3-Furyl (60, K i = 31 nM) and 3-thienyl (66, K i = 342 nM) benzene analogs show significant 5-HT 7 R affinities, although they are 2-and 4-fold less active than their pyrimidine and pyridine equivalents. 5-HT 7 R affinities of 2-furyl (63, K i = 914 nM) and 2-thienyl (69, K i = 542 nM) derivatives remain at moderate levels. Consequently, introduction of methyl groups into position 5 of 1,3-disubstituted benzene analogs results in 2-to 7-fold increases of the binding properties (64, K i = 312 nM; 67, K i = 47 nM and 70, K i = 297 nM), except for the 3-furyl ligand (61, K i = 37 nM) which stays equipotent to its unsubstituted counterpart. Surprisingly, the n-butyl substituted benzene derivatives are lower in 5-HT 7 R affinity (62, K i = 106 nM; 65, K i = 743 nM; 68, K i = 263 nM and 71, K i = 734 nM). The observed phenomenon may arise from higher lipophilicity of the ligands, which increases non-specific interactions with the tested 5-HT 7 receptor. 3-Furyl (60, Ki = 31 nM) and 3-thienyl (66, Ki = 342 nM) benzene analogs show significant 5-HT7R affinities, although they are 2-and 4-fold less active than their pyrimidine and pyridine equivalents. 5-HT7R affinities of 2-furyl (63, Ki = 914 nM) and 2-thienyl (69, Ki = 542 nM) derivatives remain at moderate levels. Consequently, introduction of methyl groups into position 5 of 1,3-disubstituted benzene analogs results in 2-to 7-fold increases of the binding properties (64, Ki = 312 nM; 67, Ki = 47 nM and 70, Ki = 297 nM), except for the 3-furyl ligand (61, Ki = 37 nM) which stays equipotent to its unsubstituted counterpart. Surprisingly, the n-butyl substituted benzene derivatives are lower in 5-HT7R affinity (62, Ki = 106 nM; 65, Ki = 743 nM; 68, Ki = 263 nM and 71, Ki = 734 nM). The observed phenomenon may arise from higher lipophilicity of the ligands, which increases non-specific interactions with the tested 5-HT7 receptor. Two selected compounds 12 and 13 with high 5-HT 7 R affinity were next evaluated in in vitro functional cAMP assay ( Figure 1 ) and their selectivity for other serotonin (5-HT 1A , 5-HT 2A , 5-HT 6 ) and dopamine D 2 receptors was investigated (Table 6 ). It was found that both 12 and 13, similarly to (2R)-1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)pyrrolidine (SB-269970) [32] -a selective 5-HT7R antagonist used as a control, dose-dependently decrease 5-CT-induced cAMP accumulation in transfected HEK cells expressing 5-HT 7 R (Figure 1 ). It has to be stressed, however, that 5-HT 7 R antagonistic properties of 12 and 13 are weaker (K B = 12 and 60 nM, respectively) than that of SB-269970 (K B = 1.9 nM) and that, unexpectedly, n-butyl derivative 13, despite showing higher affinity, is less potent 5-HT 7 R antagonist than ethyl analog 12. Alkyl substituent at position 4 also influences selectivity profile-both compounds show almost the same, high affinity for 5-HT 2A R (K i = 10 and 12 nM for 12 and 13, respectively) but n-butyl derivative is 10-and 13-fold more active than 12 at 5-HT 6 Two selected compounds 12 and 13 with high 5-HT7R affinity were next evaluated in in vitro functional cAMP assay ( Figure 1 ) and their selectivity for other serotonin (5-HT1A, 5-HT2A, 5-HT6) and dopamine D2 receptors was investigated (Table 6 ). It was found that both 12 and 13, similarly to (2R)-1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)pyrrolidine (SB-269970) [32] -a selective 5-HT7R antagonist used as a control, dose-dependently decrease 5-CT-induced cAMP accumulation in transfected HEK cells expressing 5-HT7R (Figure 1 ). It has to be stressed, however, that 5-HT7R antagonistic properties of 12 and 13 are weaker (KB = 12 and 60 nM, respectively) than that of SB-269970 (KB = 1.9 nM) and that, unexpectedly, n-butyl derivative 13, despite showing higher affinity, is less potent 5-HT7R antagonist than ethyl analog 12. Alkyl substituent at position 4 also influences selectivity profile-both compounds show almost the same, high affinity for 5-HT2AR (Ki = 10 and 12 nM for 12 and 13, respectively) but n-butyl derivative is 10-and 13-fold more active than 12 at 5-HT6 and D2 receptors. Both analogs are weak 5-HT1AR binders. 
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All air-sensitive reactions were conducted under a nitrogen atmosphere. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl immediately before use. Heteroaryllithium 
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General Methods
All air-sensitive reactions were conducted under a nitrogen atmosphere. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl immediately before use. Heteroaryllithium reagents were generated by direct lithiation of a heterocyclic substrate or by a bromine-lithium exchange reaction as previously reported [28] Final products were purified on a chromatotron using silica gel-coated rotors. Oily products were transformed into hydrobromide salts by using a general procedure [30] and the salts were crystallized from 95% ethanol. Melting points (Pyrex capillary) are not corrected. The 1 H-NMR (400 MHz) and 13 C-NMR (100 MHz) spectra of free bases and hydrobromide salts were obtained in CDCl 3 and DMSO-d 6 , respectively. Mass spectra were recorded using electrospray ionization in a positive ion mode. 1, 2, 21, 23, 24, 26, 29, 30, 32, 
Synthesis of Substituted Pyrimidines
36-46 and Quinazoline 48
A solution of the corresponding lithium reagent (10 mmol) in THF (10 mL) was stirred at´50˝C and treated dropwise with a solution of 2-chloropyrimidine, 2-chloro-5-propylpyrimidine or 2-chloroquinazoline (12 mmol) in THF (15 mL). The mixture was allowed to reach 0˝C within 2 h, then quenched with a solution of water in THF (1:5, 6 mL), stirred at 0˝C and treated with a solution of DDQ (2.3 g, 10 mmol) in THF (5 mL). After stirring for an additional 10 min at 0˝C, the mixture was treated with a cold solution of sodium hydroxide (4 M, 5 mL, 20 mmol), stirred and extracted immediately with ether/hexanes (1:1, 3ˆ10 mL). The combined extracts were dried with anhydrous sodium sulfate, decolorized by filtration through a pad of silica gel (5 g) and concentrated on a rotary evaporator. The resultant crude 4-substituted 2-chloropyrimidine or 2-chloroquinazoline was treated with a primary or secondary amine (30 mmol) in toluene (20 mL) in the presence of anhydrous potassium carbonate and the mixture was heated at 75˝C for 5-10 h, after which time a TLC analysis on silica gel eluting with ether/triethylamine (9:1) showed the absence of the substrate. Preparative chromatography was conducted eluting with ether/triethylamine/hexanes (9:5:5) to give product 1, 2, 21, 23, 24, 26, 29, 30 , 32, 36-46 (Scheme 1) and 48 (Scheme 2). 11-20, 22, 25, 27, 28, 31 Alternatively, the crude 4-substituted 2-chloropyrimidine, obtained as described above, was treated with a lithium reagent followed by aromatization with DDQ of the intermediate dihydropyrimidine under the conditions described above and the resultant crude 4,6-disubstituted 2-chloropyrimidine was allowed to react with N-methylpiperazine, as described above, to yield 4,6-disubstituted 2- (N-methylpiperazine-1-yl)pyrimidine 11-20, 22, 25, 27, 28, 31 (Scheme 1). 
Synthesis of Polysubstituted Pyrimidines
Synthesis of [N-Substituted 2-(Piperazin-1-yl)]pyrimidines 3-10 and 47
In the preparation of compounds 3-10, a mixture of 4-(3-furyl)-2-(piperazin-1-yl)pyrimidine (1, 200 mg, 0.87 mmol), synthesized as described above, and anhydrous potassium carbonate (300 mg, 2.2 mmol) in anhydrous acetonitrile (10 mL) was stirred at´10˝C and treated with ethyl bromide, propyl bromide, benzyl chloride, benzoyl chloride, 3-phenylpropyl bromide, 2-bromoethanol, ethyl 3-bromopropionate or ethyl 6-bromohexanoate (2.0 mmol) (Scheme 2). The mixture was stirred at 23˝C for 2 h and then quenched with water (2 mL) and extracted with ether (3ˆ20 mL). The extract was dried with anhydrous sodium sulfate and concentrated. Purification by chromatography eluting with dichloromethane/methanol (10:1) gave product 3-10.
In the preparation of 4-[4-(3-furyl)pyrimidin-2-yl]piperazine-1-spiro-1-morpholinium iodide (47), a mixture of compound 1 (1 mmol), 1-iodo-2-(2-iodoethoxy)ethane (1 mmol) and anhydrous potassium carbonate (140 mg, 1 mmol) in anhydrous acetonitrile (10 mL) was heated under reflux for 1 h and then quenched with water (5 mL). Product 47 was extracted with ethyl acetate and purified on a chromatotron eluting with dichloromethane/methanol (8:2). 4.5. Synthesis of 4-Dimethylamino-6-(3-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (19) This compound was obtained by:
4-(3-
(1) addition reaction of 3-furyllithium with 2,4-dichloropyrimidine; (2) aromatization of the intermediate dihydropyrimidine with DDQ by using the general procedure described above; (3) treatment of the crude product [2,4-dichloro-6-(3-furyl)pyrimidine] with dimethylamine in ethanol at 23˝C, which caused a selective displacement of the 4-chloro atom to yield 2-chloro-4-dimethylamino-6-(3-furyl)pyrimidine; and (4) the treatment of this product with 4-methylpiperazine at elevated temperature using the general procedure described above. This compound was obtained by treatment of 2,4-dichloro-6-(furan-3-yl)pyrimidine described above with 4-methylpiperazine at 75˝C by using the general procedure described above. 4-Ethyl-6-(2-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (27 The starting material, 2-chloro-4-vinylquinazoline, was obtained by the reaction of 2-chloroquinazoline with vinyllithium followed by aromatization of the resultant 4-vinyldihydroquinazoline adduct by treatment with potassium ferricyanide(III) according to the described procedure [36] .
The conjugate addition reaction of dimethylamine with 2-chloro-4-vinylquinazoline to give 2-chloro-4-(2-dimethylaminoethyl)quinazoline was conducted as described for the preparation of analogous compounds [27] . Treatment of this compound with 4-methylpiperazine to give the final product 50 was conducted by using a general procedure described above. 
Synthesis of 2-(4-Methylpiperazin-1-yl)pyridines 51-53
A mixture of furan-3-boronic acid, furan-2-boronic acid or thiophene-2-boronic acid (3.4 mmol), 4-bromo-2-chloropyrimidine (0.25 mL, 2.3 mmol), potassium carbonate (1.0 g, 7 mmol) and tetrakis(triphenylphosphine)palladium [Pd(PPh3)4, 0.2 g, 0.2 mmol] in anhydrous dioxane (6 mL) was stirred under a nitrogen atmosphere and heated under reflux for 4 days. After cooling the mixture was filtered through a 0.5-cm pad of Celite and concentrated under reduced pressure. A mixture of the crude product (2-chloro-4-heteroarylpyridine, 0.5 mmol) and 1-methylpiperazine (1 mL) in a sealed tube was heated at 200˝C for 12 h. The resultant brown oil was subjected to chromatography eluting with dichloromethane/methanol (95:5) to yield analytically pure product 51-53. 
Synthesis of Pyridines 54-59
A mixture of 4-bromo-6-methyl-2-(methylpiperazin-1-yl)pyridine or 4-bromo-2-(methylpiperazin-1-yl)pyridine (0.4 mmol), furan-3-boronic acid, furan-2-boronic acid or thiophene-2-boronic acid (0.5 mmol), tetrakis(triphenylphosphine)palladium (0.03 g, 0.03 mmol) and potassium carbonate 0.17 g, 1.1 mmol) in DMF (4.0 mL) containing water (0.3 mL) in a sealed tube under a nitrogen atmosphere was stirred at 90˝C for 12 h. After cooling, the mixture was filtered through Celite and dissolved in ethyl acetate (20 mL). The solution was washed with water (3ˆ25 mL), brine (20 mL) and concentrated under reduced pressure. The residue was subjected to chromatography eluting with hexanes/ether (4:1, 200 mL; 1:1, 150 mL) and finally with hexanes/ether/methanol (10:10:1, 200 mL) to give product 54-59. 
